drugtrial News & Analysis
2 articles
Market Mood
Abivax (ABVX) Shares Drop 32% After Ulcerative Colitis Drug Update
Shares of Abivax (ABVX) declined as much as 32% following a report on its drug for ulcerative colitis, which met clinically meaningful efficacy and a remission rate of approximately 40%. Despite achieving key endpoints, the trial revealed cancer cases in patients taking higher doses. Investigators deemed these cases unrelated to the treatment, although analysts note the results complicate the drug's prospects. This downturn follows a nearly 1,700% increase in stock value in 2025, and the company is also seen as a potential takeover target in the biotech sector.
Read More
Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
Biogen (BIIB) shares dropped 6% following the announcement of positive data from an Alzheimer's drug trial. The trial outcomes, while favorable, did not meet market expectations for immediate approval or broader commercial viability. This decline reflects investor skepticism regarding the drug's potential impact on revenue growth and market positioning. The market will be watching closely for further developments that could influence Biogen's stock performance.
Read More